Skip to content

Role of Alumina, Kali Phos and Lilium Tig in the management of Irritable Bowel Syndrome

CLINICAL VERIFICATION OF SYMPTOMS OF ALUMINA, KALI PHOS, LILIUM TIG FOR THE MANAGEMENT OF IRRITABLE BOWEL SYNDROME: A PROSPECTIVE OBSERVATIONAL STUDY - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/04/051536
Enrollment
35
Registered
2023-04-12
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K58- Irritable bowel syndrome

Interventions

Intervention1: Alumina, Lilium Tig and Kali Phos: Route of Administration is Oral. Medicines will be prescribed in 30c,200c,1M as per the requirement of case based on homeopathic principles. Pill Form

Sponsors

BAKSON HOMOEOPATHIC MEDICAL COLLEGE and HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults aged between 18 and 50 years of either sex irrespective of socio-economic group consenting to participate and suffering from irritable bowel syndrome (ICD-10 code K58). Patients fulfilling the ROME IV diagnostic criteria for IBS i.e., recurrent abdominal pain, on average at least one day per week in last three months associated with two or more of the following â?? • Related to defecation • Associated with a change in frequency of stool Associated with a change in form (appearance) of stool. Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis. Patients only with symptom severity score ranging mild and moderate.

Exclusion criteria

Exclusion criteria: Individuals having substance abuse and/or dependence or undergoing homeopathic treatment for any chronic disease within the last 6 months. Patients having clinical features like unexplained weight loss bleeding per rectum, persist Diarrhea etc. will be excluded. Pregnant and lactating females. Patients without proper follow up. Patients with other chronic illness. Patients with symptom severity score ranging in severe.

Design outcomes

Primary

MeasureTime frame
Changes in the qualitative overall score in severity of symptoms of irritable bowel syndrome by application of IBS-SSS AND QoL scales. (Medicine will be prescribed in centesimal potency) Timepoint: IBS-SSS scoring would be taken at baseline, after 3 month and after 6 months. QoL scoring would be taken at baseline, after 3month and after 6 months.

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactPreeti Laroia

BAKSON HOMOEOPATHIC MEDICAL COLLEGE and HOSPITAL

drng.2019@gmail.com9630562839

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026